Financial statements Biopol W Likwidacji
Balance sheet data of BIOPOL W LIKWIDACJI
|
Year
|
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2023
|
|---|---|---|---|---|---|---|---|
| Total assets | 294 264,11 | 221 922,71 | 163 834,79 | 158 120,37 | 155 560,81 | 660 603,54 | 660 761,95 |
| A. Fixed assets | 218 035,29 | 133 872,17 | 85 728,04 | 75 095,18 | 66 459,22 | 656 146,33 | 656 146,33 |
| B. Current assets | 76 228,82 | 88 050,54 | 78 106,75 | 83 025,19 | 89 101,59 | 4 457,21 | 4 615,62 |
| C. Share capital contributions (basic funds) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| D. Own shares (stocks) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| Total liabilities | 294 264,11 | 221 922,71 | 163 834,79 | 158 120,37 | 155 560,81 | 660 603,54 | 660 761,95 |
| A. Equity | -765 084,37 | -947 497,62 | -1 034 680,59 | -1 080 800,65 | -1 157 434,53 | -677 909,00 | -677 909,00 |
| B. Liabilities and provisions for liabilities | 1 059 348,48 | 1 169 420,33 | 1 198 515,38 | 1 238 921,02 | 1 312 995,34 | 1 338 512,54 | 1 338 670,95 |
| I. Long-term liabilities | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| II. Short-term liabilities | 1 059 348,48 | 1 169 420,33 | 1 198 515,38 | 1 238 921,02 | 1 312 995,34 | 1 298 512,54 | 1 303 432,54 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.
AD
AD